210 related articles for article (PubMed ID: 35878575)
1. Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.
Kolind S; Abel S; Taylor C; Tam R; Laule C; Li DKB; Garren H; Gaetano L; Bernasconi C; Clayton D; Vavasour I; Traboulsee A
Neuroimage Clin; 2022; 35():103109. PubMed ID: 35878575
[TBL] [Abstract][Full Text] [Related]
2. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Hauser SL; Kappos L; Arnold DL; Bar-Or A; Brochet B; Naismith RT; Traboulsee A; Wolinsky JS; Belachew S; Koendgen H; Levesque V; Manfrini M; Model F; Hubeaux S; Mehta L; Montalban X
Neurology; 2020 Sep; 95(13):e1854-e1867. PubMed ID: 32690791
[TBL] [Abstract][Full Text] [Related]
3. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
[TBL] [Abstract][Full Text] [Related]
4. Assessing the differential sensitivities of wave-CAIPI ViSTa myelin water fraction and magnetization transfer saturation for efficiently quantifying tissue damage in MS.
Elkady AM; Wu Z; Leppert IR; Arnold DL; Narayanan S; Rudko DA
Mult Scler Relat Disord; 2021 Nov; 56():103309. PubMed ID: 34688179
[TBL] [Abstract][Full Text] [Related]
5. Myelin content changes in Clinically Isolated Syndrome and Relapsing- Remitting Multiple Sclerosis: Associations with lesion type and severity of visuomotor impairment.
Panou Τ; Kavroulakis E; Mastorodemos V; Pouli S; Kalaitzakis G; Spyridaki E; Maris TG; Simos P; Papadaki E
Mult Scler Relat Disord; 2021 Sep; 54():103108. PubMed ID: 34198031
[TBL] [Abstract][Full Text] [Related]
6. Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter.
Vavasour IM; Huijskens SC; Li DK; Traboulsee AL; Mädler B; Kolind SH; Rauscher A; Moore GW; MacKay AL; Laule C
Mult Scler; 2018 Oct; 24(12):1557-1568. PubMed ID: 28782447
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies.
Cree BAC; Pradhan A; Pei J; Williams MJ;
Mult Scler Relat Disord; 2021 Jul; 52():103010. PubMed ID: 34147885
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
[TBL] [Abstract][Full Text] [Related]
9. Myelin heterogeneity for assessing normal appearing white matter myelin damage in multiple sclerosis.
Johnson P; Vavasour IM; Stojkova BJ; Abel S; Lee LE; Laule C; Tam R; Li DKB; Ackermans N; Schabas AJ; Chan J; Cross H; Sayao AL; Devonshire V; Carruthers R; Traboulsee A; Kolind SH
J Neuroimaging; 2023 Mar; 33(2):227-234. PubMed ID: 36443960
[TBL] [Abstract][Full Text] [Related]
10. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
[TBL] [Abstract][Full Text] [Related]
11. Deficient MWF mapping in multiple sclerosis using 3D whole-brain multi-component relaxation MRI.
Kitzler HH; Su J; Zeineh M; Harper-Little C; Leung A; Kremenchutzky M; Deoni SC; Rutt BK
Neuroimage; 2012 Feb; 59(3):2670-7. PubMed ID: 21920444
[TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
Arnold DL; Sprenger T; Bar-Or A; Wolinsky JS; Kappos L; Kolind S; Bonati U; Magon S; van Beek J; Koendgen H; Bortolami O; Bernasconi C; Gaetano L; Traboulsee A
Mult Scler; 2022 Oct; 28(12):1927-1936. PubMed ID: 35672926
[TBL] [Abstract][Full Text] [Related]
13. Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
Zivadinov R; Dwyer MG; Markovic-Plese S; Kennedy C; Bergsland N; Ramasamy DP; Durfee J; Hojnacki D; Hayward B; Dangond F; Weinstock-Guttman B
PLoS One; 2014; 9(3):e91098. PubMed ID: 24625687
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal microstructural MRI markers of demyelination and neurodegeneration in early relapsing-remitting multiple sclerosis: Magnetisation transfer, water diffusion and g-ratio.
York EN; Meijboom R; Thrippleton MJ; Bastin ME; Kampaite A; White N; Chandran S; Waldman AD;
Neuroimage Clin; 2022; 36():103228. PubMed ID: 36265199
[TBL] [Abstract][Full Text] [Related]
15. A pilot study comparing myelin measurements from myelin water imaging and
Vavasour IM; Vafai N; Beauchemin P; Kanjilal C; Badalan A; Shahinfard E; Laule C; Li DK; Traboulsee A; Sossi V; Kolind SH; Carruthers RL
Mult Scler Relat Disord; 2022 Dec; 68():104238. PubMed ID: 36274287
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
[TBL] [Abstract][Full Text] [Related]
17. Multislice brain myelin water fractions at 3T in multiple sclerosis.
Oh J; Han ET; Lee MC; Nelson SJ; Pelletier D
J Neuroimaging; 2007 Apr; 17(2):156-63. PubMed ID: 17441837
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of Multiple Sclerosis Lesions in Multislice Myelin Water Imaging.
Faizy TD; Thaler C; Kumar D; Sedlacik J; Broocks G; Grosser M; Stellmann JP; Heesen C; Fiehler J; Siemonsen S
PLoS One; 2016; 11(3):e0151496. PubMed ID: 26990645
[TBL] [Abstract][Full Text] [Related]
19. Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
Kappos L; Traboulsee A; Li DKB; Bar-Or A; Barkhof F; Montalban X; Leppert D; Baldinotti A; Schneble HM; Koendgen H; Sauter A; Wang Q; Hauser SL
J Neurol; 2024 Feb; 271(2):642-657. PubMed ID: 37906326
[TBL] [Abstract][Full Text] [Related]
20. A comparative assessment of myelin-sensitive measures in multiple sclerosis patients and healthy subjects.
Rahmanzadeh R; Weigel M; Lu PJ; Melie-Garcia L; Nguyen TD; Cagol A; La Rosa F; Barakovic M; Lutti A; Wang Y; Bach Cuadra M; Radue EW; Gaetano L; Kappos L; Kuhle J; Magon S; Granziera C
Neuroimage Clin; 2022; 36():103177. PubMed ID: 36067611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
